Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Am-461. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Am-461 SCHEMBL349848 | 1.00 | CYP3A4 (1.00) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| Am-461 SCHEMBL14715969 | 0.99 | CYP3A4 (0.98) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| Am-461 SCHEMBL14715972 | 0.99 | CYP3A4 (0.98) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| SCHEMBL14733229 | 0.92 | CYP3A4 (0.85) | CYP3A4PTGDR2L3MBTL1NPSR1EPHX2 | |
| SCHEMBL2361747 | 0.92 | CYP3A4 (0.85) | CYP3A4PTGDR2L3MBTL1ALDH1A1NPSR1 | |
| Am-461 SCHEMBL14715970 | 0.91 | CYP3A4 (0.84) | CYP3A4PTGDR2L3MBTL1NPSR1EPHX2 | |
| SCHEMBL349829 | 0.90 | CYP3A4 (0.82) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| SCHEMBL14733252 | 0.90 | CYP3A4 (0.81) | CYP3A4PTGDR2L3MBTL1NPSR1EPHX2 | |
| SCHEMBL350554 | 0.89 | CYP3A4 (0.81) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| SCHEMBL350178 | 0.89 | CYP3A4 (0.81) | CYP3A4PTGDR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091708-B2 | Compositions and methods targeting the Th2 pathway for the treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-17 | — | — | US | claimed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-01-21 | — | — | US | disclosed |
| US-12091708-B2 | Compositions and methods targeting the Th2 pathway for the treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-17 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3565635-B1 | METHODS FOR DIAGNOSING ASTHMA AND COMPOSITIONS FOR USE IN TARGETING THE TH2 PATHWAY IN THE TREATMENT OF ASTHMA | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116344133-A | Non-contact potentiometer with equivalent replacement potentiometer and replacement method | 上海思博机械电气有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3328500-B1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220176094-A1 | NEEDLING DEVICE AND DRUG APPLICATOR | FOLLICA INC (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3981337-A1 | NEEDLING DEVICE | Follica, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PTGDR2 4472/4885CYP3A4 2975/4885L3MBTL1 969/4885 |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885CYP3A4 2954/4885L3MBTL1 2203/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PTGDR2 4472/4885CYP3A4 2975/4885L3MBTL1 969/4885 |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885CYP3A4 2954/4885L3MBTL1 2203/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PTGDR2 4472/4885CYP3A4 2975/4885L3MBTL1 969/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PTGDR2 4472/4885CYP3A4 2975/4885L3MBTL1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.